ABOUT IIFL
CONTACT IIFL
INVESTOR RELATIONS
SENSEX 16,739.01
-95.27 -0.57%
LOGIN TO TRADE GROUP SITES
NIFTY
5,048.60
We're HIRING
FEEDBACK
Portfolio Login
Register
Share
+30.20 0.60% Quote
News
Search Home
Markets
IndiaInfoline
Markets
News News
Research
Personal Finance
Blog
Portfolio
Union Budget
SME
Earnings
About Us
PR Newswire News
PR Newswire News on IndiaInfoline.com Share |
Mutual Funds
News Latest 15:10 14:57
14:13 14:13
13:45
| Most Read Bharti Airtel gains after announcing free voice calls Gujarat Industries powers ahead after commissioning two more generators Volumes jump at NLC India counter Tata Motors gains after Jaguar Land Rover reports best ever November retail sales Indiabulls Real Estate leads gainers in 'A' group
Related Research Tanveer Shaikh, Principal Consultant, Acumen Business Consulting Your loan can be rejected without any mistake of yours! Wilting mid-caps, indices look to push forward Slowdown on the Street Positive start; data in focus
converted by W eb2PDFConvert.com
Taj Pharma Launches VENOSTOR™ (Diosmin/Hesperidin Tablets) Unique Natural Formula MUMBAI, November 4, 2016 /PRNewswire/ -Taj Pharma's VENOSTOR™ (Diosmin/Hesperidin, 30 Tablets) Improves Vascular Tone, Supports Lymphatic Drainage of the Legs and Strengthens Vascular Structures Taj Pharma launches VENOSTOR™ (Diosmin/Hesperidin Tablets). This unique natural formula combines two powerful antioxidant flavonoids to promote healthy blood flow in the legs and throughout the body. VENOSTOR (Diosmin/Hesperidin) is a unique natural formula that combines two powerful antioxidant flavonoids to support healthy blood flow in the legs and throughout the body. Derived from the sweet orange (Citrus aurantium skin), VENOSTOR (Diosmin/Hesperidin) supports circulatory health. (Photo: http://photos.prnewswire.com/prnh/20161104/436235 ) VENOSTOR 500 mg is a unique micronized purified flavonoid fraction (MPFF) containing 90% diosmin (450 mg) and 10% flavonoids (50 mg) expressed as Hesperidin. Treatment of venous disease Chronic venous disease (CVD) Hemorrhoidal disease (HD) Dietary supplement VENOSTOR 500 mg and 1000 mg (Micronized purified flavonoid fraction) Tablets:This medication is a phlebotrope: it increases the tone of veins and resistance of small blood vessels. It is shown in: • The treatment of disorders of the venous circulation such as heavy legs, pain, restlessness (irresistible urge to move the legs), night cramps, edema, trophic disorders (lesions skin due to poor blood supply) • The treatment of acute hemorrhoidal disease crisis, it is proposed in the treatment of hemorrhoidal disease background (pain, bleeding, scratch) Diosmin/Hesperidin Diosmin - flavonoid 500 mg (Generic) is an oral phlebotropic drug indicated in the treatment of venous disease, i.e., Chronic Venous Disease (CVD) and Hemorrhoidal Disease (HD). Diosmin - flavonoid 500 mg is a unique micronized purified flavonoid fraction (MPFF) containing 90% diosmin (450 mg) and 10% flavonoids (50 mg) expressed as Hesperidin. The unique active substance of DAFLON 500 mg is composed of diosmin and active concomitant flavonoid substances: hesperidin, isorhoifolin, linarin and diosmetin. Hesperidin is extracted from a species of Rutaceae aurantieae, a type of immature small orange harvested and dried in Spain, North Africa, and China. Diosmin, a member of the flavonoid family, is synthesized starting from this raw material. Diosmin - flavonoid 500 mg differs from ordinary diosmin by its unique composition in flavonoids and the unique micronization of its active substance. More details: http://tajpharmaindia.com/product/venostor-diosmin-hesperidin/ Taj Pharma has launched VENOSTOR Tablets in Indian market and also plans to launch the same for export markets. Taj Pharma also received approval for its manufacturing permission for generic versions of Diosmin/Hesperidin tablets, 500 mg, 1000 mg, and intends to commercialize this on a global scale. Other intended markets for this product are Russia, CIS, Latin America territories where the Spanish or Portuguese language packs will be launched for ease in Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Falkland Islands, French Guiana, Guatemala, Guyana, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Suriname, Uruguay and Venezuela. About Taj Pharma: Taj Pharma is one of the leading generic pharmaceutical companies in India. We hold top positions in different established markets and gradually building a strong presence in many emerging generics markets. Today, we market more than 100 branded and 500+ generics compositions to consumers in more than 28 countries and territories across the globe. Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products; more at http://www.tajpharma.com Media Contact: Shantanu Singh s.k.singh@tajpharma.com +91-22-26374592 Taj Pharmaceuticals Ltd.
Back | Next Story: Global English News Network, WION Announces its Official Launch
ABOUT IIFL
ADVERTISE
WE'RE HIRING
SITEMAP
VIDEOS
CONNECT WITH IIFL : IIFL GROUP Trade Premia Wealth
PRODUCTS & SERVICES Desktop Widget Research
Thursday, 08 December 2016 18:42 IST
CONTACT US
COMMODITY IDEAS
STOCK IDEAS
IIFL LIVE
CUSTOMER SERVICE
CORPORATE NEWS
TRADING
DISCUSS
OFFBEAT
USEFUL LINKS
CALCULATORS
Download TT
Blogs
Bschool
BSE
Income Tax
TT Login
Discussions
Economy
NSE
Home Loan EMI
TT Demo
Polls
Lifestyle
MCX
Auto Loan EMI
converted by W eb2PDFConvert.com
Flame
Mortgages
Account Details
Videos
RBI Governors
NCDEX
Education Loan EMI
Property Solutions
Insurance
Fund Transfer
Chat with Experts
Finance Ministers
Bullion Desk
HRA Exemption
Business Partners
Wealth Management
Helpdesk
Live TV
Prime Ministers
Forex Factory
Famous Speeches
Exchange Holidays
Retirement Planning
Download Forms
Stock SMS Alerts
Savings Estimator
Document & Info
GLOSSARY:
ACCOUNTANCY ADVERTISING MARKETING MATERIAL MGMT.
STOCKS:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
MUTUAL FUNDS:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
INSURANCE:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
DISCLAIMER
DISCLAIMER - RESEARCH
BUDGET
COMMERCE
DISCLAIMER - DISCUSSION BOARDS
DERIVATIVES
DISCLAIMER - CHAT
ECONOMICS
FINANCE
GENERAL MGMT.
DISCLAIMER - TWITTER
HR MGMT.
TERMS & CONDITIONS
IT
PRIVACY POLICY
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others. Copyright © 2016India Infoline Ltd. All rights Reserved. NSE SEBI Registration No. Capital Market:- INB231097537/ INF231097537/ INE231097537, CODE NO: 10975 & TC10975 CM No.: M51058 NSE SEBI Registration No. Derivatives:- INF 231097537 Clearing Member ICICI Bank Ltd. CM-C50006. BSE SEBI Registration No. Capital Market :-INB011097533 and INF011097533. Clearing No. 179 MCX Stock Exchange Limited - SEBI Registration No: INE 261097537 CODE NO. 22 | NCDEX Membership No. NCDEX-CO-04-00378 | MCX Membership No. 10470 6
converted by W eb2PDFConvert.com